{"id":"mesalazine-plus-lactobacillus-casei","safety":{"commonSideEffects":[{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mesalazine (5-aminosalicylic acid) acts as a topical anti-inflammatory agent in the colon, inhibiting prostaglandin and leukotriene production to reduce mucosal inflammation. Lactobacillus casei is a probiotic that colonizes the intestinal tract, competing with pathogenic bacteria, strengthening the intestinal barrier, and modulating local immune responses to promote a balanced microbiota.","oneSentence":"Mesalazine reduces intestinal inflammation while Lactobacillus casei provides beneficial bacteria to restore and maintain a healthy gut microbiome.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:34:24.679Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory bowel disease (ulcerative colitis and Crohn's disease)"},{"name":"Maintenance of remission in inflammatory bowel disease"}]},"trialDetails":[{"nctId":"NCT07180186","phase":"","title":"Microbiota and Probiotic Therapy in Ulcerative Colitis Patients","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-01-01","conditions":"Microbiota, Probiotic Therapy, Ulcerative Colitis","enrollment":70},{"nctId":"NCT01534754","phase":"PHASE4","title":"Mesalazine and/or Lactobacillus Casei in the Diverticular Disease of the Colon","status":"COMPLETED","sponsor":"Hospital Cristo Re","startDate":"2009-01","conditions":"Diverticular Disease of the Colon","enrollment":250}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Mesalazine plus Lactobacillus casei","genericName":"Mesalazine plus Lactobacillus casei","companyName":"Hospital Cristo Re","companyId":"hospital-cristo-re","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mesalazine, a medication used to treat conditions such as ulcerative colitis, was studied in combination with Lactobacillus casei, a probiotic, in clinical trials for the treatment of diverticular disease of the colon. The mechanism of action of Lactobacillus casei is classified as a probiotic, according to ChEMBL.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}